Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic kidney disease with moderate to severe protein in your urine and a certain level of kidney function as measured by blood and urine tests.
- You have high blood pressure (systolic at least 130 mmHg at screening and at least 120 mmHg at randomisation).
- You have been on a stable dose of an ACE inhibitor or ARB (but not both) for at least 4 weeks before screening.
- Your potassium level is within a safe range, which depends on your kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
This trial tests a new medicine called baxdrostat for people whose blood pressure stays high even when they take two or more medicines. It will be added to your current blood pressure pills to see if it helps lower your blood pressure more.
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This trial tests a new medication called baxdrostat that may help reduce thickening of the heart's main pumping chamber (left ventricular hypertrophy), which is often caused by high blood pressure. The study will see if this drug helps improve heart health in people with this condition.
Hear when a new Chronic Kidney Disease and Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.